drugset / Trial / NCT01596855
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Phase 2
Completed
96 enrolled
Kyntra Bio
Chang Zheng Hospital · collabFirst Affiliated Hospital of Zhejiang University · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabPeking Union Medical College Hospital · collabPeking University First Hospital · collabRenJi Hospital · collabRuijin Hospital · collabShenzhen People's Hospital · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease (ESRD) on maintenance hemodialysis and receiving epoetin alfa.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Roxadustat | Small molecule | — | — |
| Comparator | epoetin alfa | Protein / enzyme biologic | — | — |